Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD69 | Q07108 | 4/20 | 0.73 |
| ▸ | ELANE | P08246 | 1/20 | 0.73 |
| ▸ | TLR4 | O00206 | 3/20 | 0.43 |
| ▸ | CD14 | P08571 | 3/20 | 0.43 |
| ▸ | LY96 | Q9Y6Y9 | 3/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.32 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.32 |
| ▸ | RXRA | P19793 | 1/20 | 0.31 |
| ▸ | RXRB | P28702 | 1/20 | 0.31 |
| ▸ | RXRG | P48443 | 1/20 | 0.31 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | PPARD | Q03181 | 1/20 | 0.30 |
| ▸ | PPARA | Q07869 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2217463 | 0.85 | CD69 (1.00) | CD69ELANETLR4CD14LY96 | |
| SCHEMBL2184946 | 0.85 | CD69 (1.00) | CD69ELANETLR4CD14LY96 | |
| SCHEMBL29299544 | 0.79 | CD69 (0.86) | CD69ELANETLR4CD14LY96 | |
| SCHEMBL16545626 | 0.78 | CD69 (0.83) | CD69ELANETLR4CD14LY96 | |
| SCHEMBL38660826 | 0.76 | CD69 (0.79) | CD69ELANETLR4CD14LY96 | |
| SCHEMBL16545624 | 0.74 | CD69 (0.75) | CD69ELANETLR4CD14LY96 | |
| SCHEMBL30279470 | 0.72 | CD69 (0.72) | CD69ELANETLR4CD14LY96 | |
| SCHEMBL28137526 | 0.72 | CD69 (0.72) | CD69ELANETLR4CD14LY96 | |
| SCHEMBL23631852 | 0.71 | CD69 (0.70) | CD69ELANETLR4CD14LY96 | |
| SCHEMBL20994043 | 0.70 | CD69 (0.68) | CD69ELANETLR4CD14LY96 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230248854-A1 | METHOD FOR PRODUCING RADIOACTIVE METAL-LABELED ANTIBODY | NIHON MEDI-PHYSICS CO., LTD. (JP) | 2023-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230248854-A1 | METHOD FOR PRODUCING RADIOACTIVE METAL-LABELED ANTIBODY | CD4, PTMS, TAC3 | CD69 531/4885ELANE 3995/4885TLR4 4693/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.